These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 25756497

  • 21. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
    Gordon AM, Hurwitz S, Shapiro CL, LeBoff MS.
    Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
    [Abstract] [Full Text] [Related]

  • 22. Herpes simplex encephalitis as a complication of adjuvant chemotherapy treatment for breast cancer.
    Cathomas R, Pelosi E, Smart J, Murray N, Simmonds P.
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):292-3. PubMed ID: 15997927
    [No Abstract] [Full Text] [Related]

  • 23. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavère P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I.
    J Clin Oncol; 2004 Aug 01; 22(15):3070-9. PubMed ID: 15284257
    [Abstract] [Full Text] [Related]

  • 24. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 25. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group.
    Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A.
    Lancet; 1999 Jul 10; 354(9173):130-1. PubMed ID: 10408495
    [Abstract] [Full Text] [Related]

  • 26. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
    Debess J, Riis JØ, Engebjerg MC, Ewertz M.
    Breast Cancer Res Treat; 2010 May 10; 121(1):91-100. PubMed ID: 20306129
    [Abstract] [Full Text] [Related]

  • 27. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
    Mallmann P, Nitschmann S.
    Internist (Berl); 2010 Jul 10; 51(7):923-4. PubMed ID: 20544172
    [No Abstract] [Full Text] [Related]

  • 28. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS, International Breast Cancer Study Group Trial VIII.
    J Clin Oncol; 2007 Jan 20; 25(3):263-70. PubMed ID: 17159194
    [Abstract] [Full Text] [Related]

  • 29. Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens.
    Liu LN, Wen FH, Miaskowski C, Lin YC, Wang JS, Jeng C, Chen ML.
    J Clin Nurs; 2014 Oct 20; 23(19-20):2757-68. PubMed ID: 24393441
    [Abstract] [Full Text] [Related]

  • 30. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U.
    Anticancer Res; 2006 Oct 20; 26(2B):1519-29. PubMed ID: 16619567
    [Abstract] [Full Text] [Related]

  • 31. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.
    Kreukels BP, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, van Dam FS.
    Breast Cancer Res Treat; 2005 Nov 20; 94(1):53-61. PubMed ID: 16175317
    [Abstract] [Full Text] [Related]

  • 32. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
    Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB.
    Acta Oncol; 2009 Nov 20; 48(1):76-85. PubMed ID: 18777410
    [Abstract] [Full Text] [Related]

  • 33. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
    Land SR, Kopec JA, Yothers G, Anderson S, Day R, Tang G, Ganz PA, Fisher B, Wolmark N.
    Breast Cancer Res Treat; 2004 Jul 20; 86(2):153-64. PubMed ID: 15319567
    [Abstract] [Full Text] [Related]

  • 34. Raynaud's phenomenon after combined adjuvant chemotherapy for breast cancer.
    De Angelis R, Silveri F, Bugatti L, Filosa G.
    Chemotherapy; 2003 Sep 20; 49(5):267-8. PubMed ID: 14504440
    [No Abstract] [Full Text] [Related]

  • 35. [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].
    Pribylová O, Petruzelka L, Honová H, Fischer J, Bustová I, Siffnerová H, Kůta M, Miller V, Hacklová M, Machácek J, Kohoutek M, Vodvárka P, Kyselá T, Tajblová J, Suk J, Dorazilová V, Bauer J.
    Sb Lek; 1998 Sep 20; 99(1):25-31. PubMed ID: 9748796
    [Abstract] [Full Text] [Related]

  • 36. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U.
    Anticancer Res; 2004 Sep 20; 24(2C):1293-302. PubMed ID: 15154663
    [Abstract] [Full Text] [Related]

  • 37. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K.
    J Clin Oncol; 2003 Aug 15; 21(16):3066-71. PubMed ID: 12915595
    [Abstract] [Full Text] [Related]

  • 38. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
    Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS, Danish Breast Cancer Cooperative Group.
    Cancer; 2010 May 01; 116(9):2081-9. PubMed ID: 20186830
    [Abstract] [Full Text] [Related]

  • 39. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Zoladex Early Breast Cancer Research Association Study.
    J Clin Oncol; 2002 Dec 15; 20(24):4628-35. PubMed ID: 12488406
    [Abstract] [Full Text] [Related]

  • 40. Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer.
    Stevens A, Spooner D.
    Clin Oncol (R Coll Radiol); 2001 Dec 15; 13(6):438-40. PubMed ID: 11824881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.